Q² Solutions Announces Significant Expansion of Laboratory Operations in Scotland, UK
June 14 2021 - 8:00AM
Business Wire
Q2 Solutions, a leading global clinical trial laboratory
services organization and a wholly owned subsidiary of IQVIA, has
announced the expansion of its laboratory and operational
capabilities at its Alba Campus in Livingston, Scotland. This
expansion of central labs, genomics, flow cytometry, and
translational science laboratory services will support new growth
areas for biopharma and pharma clients around the world and drive
better patient outcomes.
The expansion includes investments in facilities enhancements
and new technologies that will strengthen capabilities and services
offered to clients, including:
- Next-generation genetic sequencing capabilities, allowing the
identification and analysis of genomic biomarkers that are becoming
increasingly important in the understanding of disease and the
development of new therapies and drugs.
- Cutting-edge flow cytometry technologies that allow the rapid
measurement and analysis of cell populations than previously
available to support clinical trials globally. This enables Q2
Solutions to greatly enhance its capability to provide useful,
unique, and highly complex data to clients.
- Creation of a dedicated clean room for peripheral blood
mononuclear cell (PBMC) isolation, used in a wide range of research
and clinical areas such as HIV research and cancer
immunotherapy.
“Expanding our capabilities at the Alba Campus reaffirms our
commitment, within an ever-changing global regulatory landscape, to
providing integrated laboratory services to regional and global
biopharmaceutical companies,” said Tony Brown, Q2 Solutions, Vice
President and General Manager, Global Central Laboratories. “Our
expanded Scottish facility reinforces our position as one of the
leading clinical trial laboratories in Europe.”
Q2 Solutions is currently the largest life science employer in
Scotland, processing nearly 5 million biological samples from
clinical trials across the world annually. The laboratory expansion
announced today, is supported by a multi-million Pound grant
awarded by Scottish Enterprise, Scotland’s national economic
development agency and creates more than 150 new jobs.
Kate Forbes MSP, Economy Secretary said, “Q2 Solutions is an
established leader in the global life sciences sector. Their
decision to significantly grow their presence at the Alba Campus
represents a vote of confidence for Scotland and our increasing
stature as a hub for life sciences. The Scottish Government is
delighted to support this exciting initiative and welcomes the
highly skilled jobs that will be created.”
About Q2 Solutions
Q2 Solutions is a leading global clinical trial laboratory
services organization providing comprehensive testing, project
management, supply chain, biorepository, biospecimen and consent
tracking solutions. Leveraging our next generation technologies, we
deliver agile and precise services designed to meet the diverse
needs of our clients. We provide scientific expertise and
innovative solutions for ADME, bioanalytical, genomics, vaccines
and central laboratory services, including flow cytometry, anatomic
pathology, immunoassay, molecular and companion diagnostics, with
meticulous regional and global clinical trial implementation
support and high-quality data delivery. At Q2 Solutions, our work
is rooted in research, grounded in collaboration, and guided by our
passion to turn the hope of patients and caregivers around the
world into the help they need. To learn more, visit
www.q2labsolutions.com.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced
analytics, technology solutions, and clinical research services to
the life sciences industry. IQVIA creates intelligent connections
across all aspects of healthcare through its analytics,
transformative technology, big data resources and extensive domain
expertise. IQVIA Connected Intelligence™ delivers powerful insights
with speed and agility — enabling customers to accelerate the
clinical development and commercialization of innovative medical
treatments that improve healthcare outcomes for patients. With
approximately 72,000 employees, IQVIA conducts operations in more
than 100 countries.
IQVIA is a global leader in protecting individual patient
privacy. The company uses a wide variety of privacy-enhancing
technologies and safeguards to protect individual privacy while
generating and analyzing information on a scale that helps
healthcare stakeholders identify disease patterns and correlate
with the precise treatment path and therapy needed for better
outcomes. IQVIA’s insights and execution capabilities help biotech,
medical device and pharmaceutical companies, medical researchers,
government agencies, payers and other healthcare stakeholders tap
into a deeper understanding of diseases, human behaviors, and
scientific advances, to advance their path toward cures. To learn
more, visit www.iqvia.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210614005236/en/
Nick Childs, IQVIA Investor Relations (Nchilds@us.imshealth.com)
+1.973.316.3828 Tor Constantino, IQVIA Media Relations
(tor.constantino@iqvia.com) +1.484.567.6732
IQVIA (NYSE:IQV)
Historical Stock Chart
From Aug 2024 to Sep 2024
IQVIA (NYSE:IQV)
Historical Stock Chart
From Sep 2023 to Sep 2024